Home
Latest
Finance
IPO
ETF
Tech
Overseas
Video
Research
Topic
Download App
简
繁
简
繁
EN
Home
Latest
Finance
IPO
ETF
Tech
Overseas
Video
Research
Topic
HOME
·
Clinical Trial
CARSGEN-B (02171.HK): First Patient Dose of CT0596 in China Phase I
Tags:
CARSGEN-B
02171.HK
Clinical Trial
2026-10-13
EDDING GENOR (06998.HK): GB268 Colorectal Cancer Phase II IND Approved
Tags:
EDDING GENOR
06998.HK
Clinical Trial
2026-10-11
CSPC PHARMA (01093.HK): 8 trials to feature at ESMO 2026, two as LBAs
Tags:
CSPC PHARMA
01093.HK
Clinical Trial
2026-10-05
QYUNS-B (02509.HK): Oturkibart PN Phase III data at EADV 2026
Tags:
QYUNS-B
02509.HK
Clinical Trial
2026-10-02
HENGRUI PHARMA (01276.HK): Two Drugs Win Clinical Trial Approval in China
Tags:
HENGRUI PHARMA
01276.HK
Clinical Trial
2026-09-22
CF PHARMTECH (02652.HK): ICF004 Phase I First Subject Dosed for ILD
Tags:
CF PHARMTECH
02652.HK
Clinical Trial
2026-09-22
HENGRUI PHARMA (01276.HK): SHR-4595 Gets Clinical Trial Approval in China
Tags:
HENGRUI PHARMA
01276.HK
Clinical Trial
2026-09-22
CSPC PHARMA (01093.HK): SYH9102, World's First Ready-to-use Goserelin Extended-release Injection, Cleared for Clinical Trials in China
Tags:
CSPC PHARMA
01093.HK
Clinical Trial
2026-09-09
ALEBUND-B (09637.HK): FDA Clears IND for First-in-class IgA Protease AP308 in IgA Nephropathy; First-in-human Trial to Commence
Tags:
ALEBUND-B
09637.HK
Clinical Trial
2026-09-08
CSPC PHARMA (01093.HK): Innovative Chemical Drug SYH2083 Eye Drops Obtains Clinical Trial Approval in China for Dry Eye Disease
Tags:
CSPC PHARMA
01093.HK
Clinical Trial
2026-09-08
CSPC PHARMA (01093.HK): Phase II clinical trial of SYH2085 tablets for uncomplicated influenza in adults officially initiated in China
Tags:
CSPC PHARMA
01093.HK
Clinical Trial
2026-09-07
HENGRUI PHARMA (01276.HK): Clinical trials approved for HRS-6209 capsules and HRS-4508 tablets in advanced breast cancer and solid tumors
Tags:
HENGRUI PHARMA
01276.HK
Clinical Trial
2026-09-07
HENGRUI PHARMA (01276.HK): HRS-1597 tablets approved for clinical trial for weight management
Tags:
HENGRUI PHARMA
01276.HK
Clinical Trial
2026-09-07
HENGRUI PHARMA (01276.HK): SHR-1179 injection approved for clinical trial, targeting weight management indication
Tags:
HENGRUI PHARMA
01276.HK
Clinical Trial
2026-09-07
LAEKNA-B (02105.HK): First subject enrolled in Phase I clinical study of LAE118 for advanced solid tumours
Tags:
LAEKNA-B
02105.HK
Clinical Trial
2026-09-01
CSPC PHARMA (01093.HK): Phase I clinical trial of SYH2092 for weight management initiated in China
Tags:
CSPC PHARMA
01093.HK
Clinical Trial
2026-09-01
ABBISKO-B (02256.HK): First patient dosed in Phase I trial of pan-KRAS inhibitor ABSK211, preclinically covering multiple KRAS alterations
Tags:
ABBISKO-B
02256.HK
Clinical Trial
2026-08-31
HUTCHMED (00013.HK): SANOVO Phase III of ORPATHYS plus TAGRISSO meets primary endpoint in first-line EGFR-mutant NSCLC, with significant PFS benefit
Tags:
HUTCHMED
00013.HK
Clinical Trial
2026-08-31
ASCLETIS-B (01672.HK): First subject dosed in global Phase III program of oral GLP-1 agonist ASC30 for long-term weight management, targeting ~4,600 subjects
Tags:
ASCLETIS-B
01672.HK
Clinical Trial
2026-08-30
CSPC PHARMA (01093.HK): Phase II Clinical Trial of SYH2069 Injection for Weight Management in Overweight or Obese Adults Launched at First Study Site in China
Tags:
CSPC PHARMA
01093.HK
Clinical Trial
2026-08-28
Previous
1
2
3
4
5
Next
Finance
METIS TECHBIO-P (07666.HK): plans H-share buyback of up to HKD 300m
Finance
HENGRUI PHARMA (01276.HK): hetrombopag NDA accepted in China
Research
HK Stock Connect Daily: NETEASE -17.60% on Gaming Slump - 20261120
Finance
WATER OASIS GP (01161.HK): FY profit seen doubling to HKD 165-175m
Research
HK AI Concept Stock Daily: BABA-W +3.48% Defies Slump - 20261120
Research
Hong Kong Recently Listed Stocks Daily Report: BRAINAURORA-B Rises 39.50% to Lead; Intelligent Driving and Smart Parking Gain Traction-20261120
Finance
NewTimeSpace | HK Close: HSI -1.89%, Semis and Hardware Lead Declines
Research
HK shares ETFs Daily Report: Fubon Taiwan Semiconductor ETF Falls 9.81% as CSI 300 and India Themes Rise-Nov 20, 2026
Research
Offshore Trust Insight | NIO-SW (09866.HK) -5.07%; Users Trust 50m
Research
HK Stock Connect Insight | RA MATERIALS (09607.HK) -13.26%; Stake Rise
Scan QR Code
Download App